IBRXImmunityBio, Inc.Running, no new patients
A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
Non-muscle Invasive Bladder Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 369 (final count)
- Started
- Jul 21, 2014
- Main results expected
- Sep 30, 2026
- Fully finished
- Mar 4, 2039
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Complete Response (CR) Rate
Measured over: 6 Months
Disease Free Survival (DFS)
Measured over: 13 Years and 3 Months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT02138734 · record last updated 2026-03-31 · checked 2026-11-09 15:47 UTC